STOCK TITAN

Biovie Inc - BIVI STOCK NEWS

Welcome to our dedicated page for Biovie news (Ticker: BIVI), a resource for investors and traders seeking the latest updates and insights on Biovie stock.

BioVie Inc. (BIVI) is a clinical-stage biotechnology company pioneering novel therapies for chronic liver disease complications and neurodegenerative disorders. This page serves as the definitive source for all official company updates, including clinical trial progress, regulatory milestones, and strategic developments.

Access real-time announcements about BIV201 for liver ascites management and bezisterim for Alzheimer’s/Parkinson’s research. Stay informed on orphan drug designations, partnership agreements, and financial disclosures that shape BioVie’s innovative pipeline.

All content is rigorously curated to provide investors and researchers with compliant, actionable insights. Bookmark this hub for authoritative updates on therapies addressing critical unmet medical needs through advanced clinical research.

Rhea-AI Summary

BioVie Inc. (NASDAQ: BIVI) has announced the pricing of a registered direct offering of 4,443,000 shares of common stock at $1.50 per share, raising gross proceeds of $6,664,500. The company is also issuing unregistered warrants to purchase up to 4,443,000 shares in a concurrent private placement. These warrants have an exercise price of $1.37 per share, will be exercisable after six months, and expire five years from the initial exercise date.

The offering is expected to close around October 22, 2024. BioVie plans to use the net proceeds for working capital and general corporate purposes. ThinkEquity is acting as the sole placement agent for this offering, which is being conducted under a shelf registration statement filed with the SEC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.91%
Tags
private placement offering
-
Rhea-AI Summary

BioVie Inc. (NASDAQ: BIVI) has received a Notice of Allowance from the Japan Patent Office for its novel liquid formulation of terlipressin acetate. This formulation, which is stable at room temperature for up to 24 months, can be packaged in a pre-filled syringe, offering significant advantages for treating patients with cirrhosis and ascites, particularly in home-care settings.

The company has now secured patents for this formulation in the United States, India, Japan, and Chile, with pending applications in eight additional markets. This development strengthens BioVie's intellectual property protection and enhances the value of its BIV201 program, which aims to provide a more patient-centric ambulatory treatment for ascites and hepatic failure.

Terlipressin is currently used in over 40 countries to treat complications of liver cirrhosis, but the recent US approval is for a lyophilized powder form requiring reconstitution and refrigeration. BioVie's liquid formulation offers improved convenience and safety, potentially benefiting patients with cirrhosis and ascites, who currently face treatment options and poor survival rates.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.51%
Tags
none
-
Rhea-AI Summary

RedChip Companies will air interviews with BioVie, Inc. (Nasdaq:BIVI) and Genetic Technologies on Bloomberg TV this Saturday, October 12, at 7 p.m. ET. The interviews will feature:

1. Cuong Do, President and CEO of BioVie, discussing the company's late-stage clinical programs for neurodegeneration and liver disease. Key points include:

  • Bezisterim's ability to modulate TNFα production, leading to clinical improvements
  • Planned Phase 2b trial for Parkinson's in late 2024
  • Upcoming Phase 3 trial for Alzheimer's in late 2025
  • Ongoing partnering discussions for bezisterim's geographic rights
  • Plans for an ascites Phase 3 trial

2. Peter Rubinstein, Executive Chairman of Genetic Technologies, providing a corporate update on:

  • EasyDNA platform with $7 million in annual recurring revenues
  • Expanding product portfolio with over 50 risk assessment tests
  • B2B commercialization strategy for geneType multi-risk test
  • Focus on direct-to-consumer testing programs
  • Recent corporate restructure to reduce cash burn
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.85%
Tags
none
Rhea-AI Summary

BioVie Inc. (NASDAQ: BIVI) has received a Notice of Allowance from the USPTO for a patent application covering a novel liquid formulation of terlipressin acetate. This formulation demonstrates room-temperature stability for up to 24 months and can be packaged in a pre-filled syringe. The patent is expected to be listed in the Orange Book and supports BioVie's development of a more patient-centric ambulatory treatment for patients with ascites and hepatic failure.

The liquid formulation offers significant advantages over the recently approved lyophilized powder form of terlipressin in the US, which requires reconstitution and refrigerated storage. BioVie's formulation could improve dosing convenience and safety, particularly in home-care settings. The company has also secured patents for this formulation in India and Chile, with applications pending in nine additional markets.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.17%
Tags
none
-
Rhea-AI Summary

BioVie Inc. (Nasdaq: BIVI), a clinical-stage company developing therapies for liver disease and neurological disorders, has closed its previously announced public offering. The offering included 1,360,800 shares of common stock, 600,000 pre-funded warrants, and warrants to purchase up to 1,960,800 shares at a combined price of $1.53 per share or pre-funded warrant with associated common warrant. The common warrants have an exercise price of $1.53 and are exercisable for five years. The offering raised approximately $3,000,000 in gross proceeds. BioVie plans to use the net proceeds for working capital and general corporate purposes. ThinkEquity acted as the sole placement agent for this best efforts offering, which was conducted under a shelf registration statement filed with the SEC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.5%
Tags
-
Rhea-AI Summary

BioVie Inc. (NASDAQ: BIVI), a clinical-stage company developing drug therapies for liver disease and neurological disorders, has announced the pricing of a public offering. The offering includes 1,960,800 shares of common stock (or pre-funded warrants) and warrants to purchase up to 1,960,800 shares at a combined price of $1.53 per share and associated warrant. The warrants have an exercise price of $1.53 and will be exercisable for five years upon issuance.

The company expects to raise approximately $3,000,000 in gross proceeds, which will be used primarily for working capital and general corporate purposes. The offering is set to close on September 25, 2024, subject to customary closing conditions. ThinkEquity is acting as the sole placement agent for this best efforts public offering.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-57.86%
Tags
Rhea-AI Summary

BioVie Inc. (NASDAQ: BIVI), a clinical-stage company focused on developing innovative drug therapies for advanced liver disease and neurological disorders, has announced its intention to conduct a public offering of common stock shares and accompanying purchase warrants. The company may also offer pre-funded warrants in lieu of common stock. ThinkEquity is acting as the sole placement agent for this best efforts offering.

The offering's proceeds are intended primarily for working capital and general corporate purposes. The securities will be offered under a shelf registration statement filed with the SEC. A preliminary prospectus supplement and accompanying prospectus will be available from ThinkEquity and the SEC's website. The offering's completion is subject to market conditions, with no guarantees regarding its execution or terms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-57.86%
Tags
-
Rhea-AI Summary

BioVie Inc. (NASDAQ: BIVI) has secured all scientific approvals needed to receive an additional $12.6 million in grant funding from the U.S. Department of Defense for a planned Phase 2 trial of bezisterim in long COVID. The U.S. Army Medical Research and Development Command, Office of Human Research Oversight (OHRO) approved BioVie's plan to evaluate bezisterim for treating neurological symptoms associated with long COVID. This approval follows the FDA's Safe to Proceed designation in August 2024.

The Phase 2 study, expected to commence by early 2025, will be a randomized, placebo-controlled trial involving approximately 200 patients to assess the safety, tolerability, and potential efficacy of bezisterim in reducing neurocognitive symptoms of long COVID over a 3-month treatment period. Bezisterim, which can cross the blood-brain barrier, targets inflammation via NF-kB activation, addressing a suspected underlying cause of long COVID symptoms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.95%
Tags
clinical trial covid-19
-
Rhea-AI Summary

BioVie Inc. (NASDAQ: BIVI) has received FDA authorization for its Investigational New Drug (IND) application to evaluate bezisterim in a Phase 2 trial for treating neurological symptoms associated with long COVID. This milestone puts BioVie on track to receive an additional $12.6 million in grant funding from the U.S. Department of Defense and initiate the trial. The planned study will be a randomized, placebo-controlled, multicenter trial involving approximately 200 patients to assess the safety and efficacy of bezisterim over a 3-month treatment period.

Long COVID affects about 5.5% of U.S. adults, with approximately 3.6 million people reporting significant activity modifications due to the illness. Bezisterim's potential to modulate inflammation by activating NF-kB and its ability to permeate the blood-brain barrier make it a promising candidate for addressing the underlying mechanisms of long COVID symptoms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.96%
Tags
Rhea-AI Summary

BioVie Inc. (NASDAQ: BIVI) presented clinical data on bezisterim at the 11th Aging Research and Drug Discovery Meeting, revealing its potential to modulate inflammation and the biological aging process. Key findings include:

1. Patients treated with bezisterim experienced a 2-4 year age deceleration advantage compared to placebo.

2. Bezisterim modulated DNA methylation of proinflammatory genes and appeared to promote the transition of M1 proinflammatory to M2 anti-inflammatory macrophages.

3. The drug was associated with a 1.5 to 2.3 'fold enrichment' on gene control for hundreds of genes in pathways linked to neurodegenerative disorders and biological processes.

These results suggest bezisterim's potential to impact various age-related diseases and inflammation-related conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3%
Tags
Biovie Inc

Nasdaq:BIVI

BIVI Rankings

BIVI Stock Data

15.51M
15.97M
13.09%
4.27%
8.88%
Biotechnology
Pharmaceutical Preparations
Link
United States
CARSON CITY